mRNA vaccine boosting enhances antibody responses against SARS-CoV-2 Omicron variant in individuals with antibody deficiency syndromesmRNA 백신 부스팅은 항체 결핍 증후군이 있는 개인에서 SARS-CoV-2 Omicron 변이체에 대한 항체 반응을 향상시킵니다Article Published on 2022-06-212022-09-11 Journal: Cell Reports Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Anti-spike antibody antibody deficiency syndrome Antibody Response Antibody titer Antibody titers binding combined variable antibody deficiency comparable coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 deficiency Delta develop domain ENhance Fcγ receptor FcγR healthy donors humoral immune response Hypogammaglobulinemia immune immune response immune responses Immunity immunization Immunoglobulin immunoglobulin replacement therapy individual MOST mRNA mRNA vaccination mRNA vaccine mRNA vaccines neutralization neutralizing activities Neutralizing activity neutralizing antibody titers omicron primary antibody Protective RBD receptor replacement therapy respiratory response SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variants serum severe acute respiratory syndrome Coronavirus specific antibody deficiency sustained syndrome tested titers vaccinated individual vaccination Vaccine variant virus [DOI] 10.1016/j.xcrm.2022.100653 PMC 바로가기 [Article Type] Article
Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease체액성 면역결핍증 환자에서 SARS-CoV-2에 대한 mRNA 백신에 대한 체액 반응Article Published on 2022-06-092022-09-12 Journal: PLoS ONE [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] 95%CI Analysis anti-S anti-S antibody anti-SARS-CoV-2 antibody baseline BNT162b2 cross-sectional CVID dose evaluate evaluated healthy control healthy controls hospitalizations humoral humoral immune response humoral immune responses Humoral response Hypogammaglobulinemia IgG immune response immunodeficiency immunodeficiency disease immunoglobulin replacement therapy immunosuppressive drug immunosuppressive drugs individual induce Infection Mild moderate mRNA vaccine mRNA-1273 mRNA-based vaccine Patient patients patients with moderate Prevent proportion robust SARS-CoV-2 Spike protein subject the antibody response the spike protein vaccination vaccine dose vaccine doses were measured [DOI] 10.1371/journal.pone.0268780 PMC 바로가기 [Article Type] Article
Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab오크렐리주맙으로 치료받은 다발성 경화증 환자의 저감마글로불린혈증, 감염 및 COVID-19Article Published on 2022-06-012022-09-12 Journal: Multiple sclerosis and related disorders [Category] MERS, 진단, [키워드] 95%CI age baseline Characteristics COVID-19 database determine disease enrolled Follow-up Hospitalization Hypogammaglobulinemia IgG IgM IgM and IgG Immunoglobulin increased the risk Infection infections information Level median multiple sclerosis number Ocrelizumab rate of infection real-world data risk searched Sex statistically significant treated Treatment were measured [DOI] 10.1016/j.msard.2022.103798 PMC 바로가기 [Article Type] Article
Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International StudyClinical Research Published on 2022-06-012024-09-04 Journal: Journal of the American Society of Nephrology [Category] 대상포진, [키워드] biologics children Hypogammaglobulinemia nephrotic syndrome neutropenia rituximab [DOI] 10.1681/ASN.2021111472 PMC 바로가기 [Article Type] Clinical Research
Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway장기간의 중증 SARS-COV-2 감염을 치료하거나 예방하기 위한 B-세포 고갈 제제를 사용하는 환자의 임상 관리: 치료 경로 정의Article Published on 2022-05-272022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료제, [키워드] Activation Adverse drug reactions agent anti-CD20 anti-CD20 agent anti-SARS-CoV-2 anti-SARS-CoV-2 monoclonal antibody antibody Antiviral B cell B-cell B-cells depletion Case series case sery Characteristics clinical collected Combined therapy convalescent convalescent plasma COVID-19 COVID-19 patient Day demographic demographic characteristics Depletion effective enrolled glycoprotein hospitalized patient Hypogammaglobulinemia immune Immunocompromised Immunocompromised patients Immunosuppressed immunosuppressed patients Immunotherapy Infection Infectious diseases Inpatient interstitial pneumonia intravenous Italy kinetic Lazzaro Spallanzani longitudinal study mandatory median medical history monoclonal monoclonal antibodies monoclonal antibody Neutralizing antibodies outcome oxygen Passive immunotherapy Patient patients persistence Prolonged Protein RDV risk Rome SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein severe SARS single-center spike spike glycoprotein Spike protein steroid Steroids subjects T cell T cell activation T cells the patient therapy treated treated patient Treatment Virological with COVID-19 [DOI] 10.3389/fimmu.2022.911339 PMC 바로가기 [Article Type] Article
COVID-19 Vaccine Responses in Patients With Plasma Cell Dyscrasias After Complete Vaccination완전한 백신 접종 후 형질 세포 이상증 환자의 COVID-19 백신 반응Article Published on 2022-05-012022-09-11 Journal: Clinical lymphoma, myeloma & leukemia [Category] MERS, 진단, 치료법, [키워드] adenoviral vector vaccine Administered age anti-CD38 anti-spike antibodies anti-spike antibody antibody Antibody Response Antibody responses Antibody testing Cell clinical history Complete consecutive patient consecutive patients COVID-19 COVID-19 vaccination detectable drug therapy dyscrasia evaluated Evidence evidence of examined functional heterologous mRNA vaccine Hypogammaglobulinemia Immunocompromised increased risk Infection IVIG Johnson & Johnson Johnson & Johnson management Moderna monoclonal antibody monoclonal antibody therapy mRNA vaccine Multiple Multiple myeloma Multivariate analysis negatively affected nucleocapsid Patient plasma Plasma cell Plasma Cell Dyscrasias Quantitative receiving response responses Roche SARS-CoV-2 second dose serologic Serologic response spike Spike antibody detection tested the timing therapy Treatment vaccination Vaccine Vaccine boosters. Vaccines were excluded were measured [DOI] 10.1016/j.clml.2021.11.001 PMC 바로가기 [Article Type] Article
The humoral response to SARS-COV-2 vaccines in MS patients: A case series exploring the impact of DMT, lymphocyte count, immunoglobulins, and vaccine type다발성경화증 환자에서 SARS-COV-2 백신에 대한 체액성 반응: DMT, 림프구 수, 면역글로불린 및 백신 유형의 영향을 탐구하는 사례 시리즈Article Published on 2022-05-012022-09-11 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] Affect age antibody association B-cell case sery CD19 Cell Certain disease correlation COVID19 depleting detectable disease disease phenotype disorder DMT dose Exploratory analysis females fumarate Gender group humoral Humoral response Hypogammaglobulinemia immune response immunoglobulins immunological immunological characteristics lymphocyte Lymphocyte count lymphocyte counts lymphopenia Mild Multiple multiple sclerosis no differences Patient performed positive positive patient positive patients Quantitative response to vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccines SARS-CoV2 seroconversion rate seroconversion rates Spike protein subgroup subgroups tested the spike protein therapy vaccination Vaccine vaccine response Vaccines variable verification [DOI] 10.1016/j.msard.2022.103785 PMC 바로가기 [Article Type] Article
Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia Reviews Published on 2022-04-192022-10-05 Journal: Bone marrow transplantation [Category] 치료제, [키워드] accelerate administration antibody available data Bacterial infection benefit Blood Cell Characteristics chimeric antigen receptor clinical clinical trial CLL deficiency demonstrated disease dosage Efficacy Evidence Hematological malignancy heterogeneous HSCT HSCT recipient Hypogammaglobulinemia IgG immune Immunoglobulin immunoglobulin replacement therapy infection risk leukemia Meta-analysis monoclonal antibody Mortality MOST Multiple myeloma Other other disease Patient Prophylactic randomized trial regimen subsequent T-cell therapy utility [DOI] 10.1038/s41409-022-01680-z [Article Type] Reviews
Response to Severe Acute Respiratory Syndrome Coronavirus 2 Initial Series and Additional Dose Vaccine in Patients With Predominant Antibody DeficiencyOriginal Article Published on 2022-04-022023-06-16 Journal: The journal of allergy and clinical immunology. In [Category] COVID19(2023년), MERS, SARS, [키워드] Additional dose anti-nucleocapsid antibody anti-spike antibody COI, Cutoff index common variable immunodeficiency COVID-19 COVID-19, Coronavirus disease 2019 CVID CVID, Common variable immunodeficiency Humoral immunodeficiency Hypogammaglobulinemia IgG subclass deficiency Neutralization assay PAD, Predominant antibody deficiency Predominant antibody deficiency SAD, Specific antibody deficiency SARS-CoV-2 SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 specific antibody deficiency vaccine response [DOI] 10.1016/j.jaip.2022.03.017 PMC 바로가기 [Article Type] Original Article
Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency공통 가변성 면역 결핍증에서 항-SARS-CoV-2 백신의 면역원성Article Published on 2022-02-012022-09-12 Journal: Journal of Clinical Immunology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] administration anti-SARS-CoV-2 vaccine antibodies antibody Antibody Response Antigen antigens Autoimmunity Cell cellular response characterized common common variable immunodeficiency COVID-19 COVID-19 vaccination COVID-19 vaccine CVID dose ELISA healthy control humoral Hypogammaglobulinemia IFN-γ immune immune response immunization immunodeficiency immunogenicity mechanism neutralizing antibody Patient patients Primary Immunodeficiency Primary immunodeficiency diseases prospectively studied Protective receiving SARS-CoV-2 second dose significantly lower subject T cell T cell response the vaccine therapy vaccination Vaccine variable was measured [DOI] 10.1007/s10875-021-01174-5 PMC 바로가기 [Article Type] Article